{"id":"fada-remifentanilo","safety":{"commonSideEffects":[{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Muscle rigidity"},{"rate":null,"effect":"Nausea and vomiting"}]},"_chembl":{"chemblId":"CHEMBL1005","moleculeType":"Small molecule","molecularWeight":"376.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Remifentanil activates mu opioid receptors, which are G-protein coupled receptors that modulate pain perception and consciousness. It is characterized by rapid onset and offset due to metabolism by non-specific plasma and tissue esterases, making it suitable for short procedures and intravenous anesthesia. The drug crosses the blood-brain barrier quickly to produce potent analgesic and sedative effects.","oneSentence":"Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:32.729Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intravenous analgesia and sedation during general anesthesia"},{"name":"Analgesia in mechanically ventilated patients in intensive care settings"}]},"trialDetails":[{"nctId":"NCT02048293","phase":"PHASE4","title":"Pharmacodynamic Differences Between Branded and Unbranded Remifentanil Molecules","status":"COMPLETED","sponsor":"Fundación Universitaria de Ciencias de la Salud","startDate":"2012-10","conditions":"Pain","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fada Remifentanilo","genericName":"Fada Remifentanilo","companyName":"Fundación Universitaria de Ciencias de la Salud","companyId":"fundaci-n-universitaria-de-ciencias-de-la-salud","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation. Used for Intravenous analgesia and sedation during general anesthesia, Analgesia in mechanically ventilated patients in intensive care settings.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}